Archive for January 25th, 2010
Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) today issued the following statement regarding the U.S. Food and Drug Administration (FDA) approval of AMPYRA™ (dalfampridine) as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. AMPYRA™ will be marketed in the U.S…
Biogen Idec (NASDAQ: BIIB) today issued the following statement regarding the United States (U.S.) Food and Drug Administration (FDA) approval of AMPYRA™ (dalfampridine) to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. The U.S. FDA approval was granted on January 22, 2010. AMPYRA will be marketed in the U…
Title: FDA Warns of Heart Risks With Diet Drug
Category: Health News
Created: 1/21/2010 2:10:00 PM
Last Editorial Review: 1/22/2010
The Food and Drug Administration has approved the drug fampridine-SR for the treatment of multiple sclerosis…
ABOUT
Your online resource center for Multiple Sclerosis Information
RECENT POSTS
Best Selling Book
Subscriptions
RSSContributors
Archives
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008